Supplementary Figure 1

In vivo delayed-type hypersensitivity to Mycobacterium tuberculosis on day 13 after preventive treatment of AA, i.e. when the clinical differences between the accelerating and ameliorating anti-CD4 mAbs were maximal. The data are expressed as means ± SEM (n = 6 for all groups, one representative of three in vivo experiments) of the difference between the swelling of the left (mycobacterium-treated) and the right (PBS-treated) ears. ^*P ≤ 0.05 in comparison with PBS-treated rats.